AAOpt 2023: Update from BioTissue

News
Article

Roger Kennedy, Director of Marketing of BioTissue, shares an overview on a poster on cryopreserved amniotic membrane and the effectiveness in moderate to severe dry eye disease over a 3 month timeframe, presented during the 2023 American Academy of Optometry meeting in New Orleans.

Editor's note: This transcript has been edited for clarity.

Roger Kennedy:

Hi, my name is Roger Kennedy. I'm the Director of Marketing for BioTissue. Today I want to talk to you about the poster that's going to be presented tomorrow at Academy of Optometry. It's virtually a poster on cryopreserved amniotic membrane and the effectiveness in moderate to severe dry [eye] disease over a 3 month timeframe.

The highlights of the story, or of the poster rather, is basically you have cryopreserved amniotic membrane being shown to reduce the signs and symptoms of moderate to severe dry [eye] disease. This was defined as either [stage] 3 or [stage] 4 dry eye disease, and we saw a reduction in signs and symptoms.

Then, what's new about this? This is a paper that has been published quite a bit ago, but we re-looked at the paper and evaluated at what time does it take for cryopreserved amniotic membrane to be effective in reducing the signs and symptoms. We saw no statistical significance between day 2 and day 5, which opens our eyes as far as the ability to have onset action of effectiveness.

Traditionally, we've been recommending anywhere from 3 to 5 days. Now, we are starting to have some sort of evidence to show that in as little as 2 days you can be effective in treating dry disease.

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Shawn Hobbs, OD, previews the annual NOA convention, which takes place in Columbus, Ohio, July 10-12, 2025.
Clark Chang, OD, MSA, MSc, FAAO, gave a presentation alongside Susan Gromacki, OD, MS, FAAO, FSLS, at this year's Optometry's Meeting.
Selina McGee, OD, FAAO, Dipl ABO, shares key takeaways and a personal anecdote relating to the State of Dry Eye survey results.
Devin Sasser, OD, shares his excitement for Acuvue Oasys MAX 1-Day multifocal for astigmatism, the first and only daily disposable multifocal toric contact lens.
Reviewing the State of Dry Eye Survey with Selina McGee, OD, FAAO, Dipl ABO.
Jessilin Quint, OD, MBA, FAAO, outlines her AOA's Optometry's Meeting 2025 presentation on nutrition and its impact on ocular health.
Carolyn Majcher, OD, FAAO, detailed a talk she gave alongside Mary Beth Yackey, OD, at Optometry's Meeting 2025.
Shelby Brogdon, OD, details opportunities for practices to answer the patient's concerns from the chair before they hit the internet for their contact lens needs.
Christi Closson, OD, FAAO, shares her excitement for the new Acuvue Oasys MAX 1-Day multifocal for astigmatism
Karen R. Hoffman, OD, shares how customizable scleral lenses can transform vision for patients with complex corneas, achieving 20/20 outcomes and enhanced comfort.
© 2025 MJH Life Sciences

All rights reserved.